1. Scrip
  2. >>Business

BioGaia and Ferring extend probiotic sales agreement

 
• By Simon Varcoe

BioGaia, a Swedish biotechnology company, has extended its agreement withFerring Pharmaceuticals over BioGaia's probiotics drops. The Swiss-based biopharmaceutical company has the rights to sell BioGaia's probiotic drops in Ireland and exclusive selling rights to the probiotic drops and tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and the United Arab Emirates. BioGaia's products are based primarily on the lactic acid bacterium Lactobacillus reuteri, which the company claims has probiotic, health-enhancing effects. The two companies signed an initial agreement in March 2006, allowing Ferring to sell the drops in Spain, Portugal, Czech Republic and Hungary. The agreement was extended to Mexico, Brazil and Greece in August.

BioGaia, a Swedish biotechnology company, has extended its agreement withFerring Pharmaceuticals over BioGaia's probiotics drops. The Swiss-based biopharmaceutical company has the rights to sell BioGaia's probiotic drops in Ireland and exclusive selling rights to the probiotic drops and tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and the United Arab Emirates. BioGaia's products are based primarily on the lactic acid bacterium Lactobacillus reuteri, which the company claims has probiotic, health-enhancing effects. The two companies signed an initial agreement in March 2006, allowing Ferring to sell the drops in Spain, Portugal, Czech Republic and Hungary. The agreement was extended to Mexico, Brazil and Greece in August.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

More from Scrip